-
Je něco špatně v tomto záznamu ?
Identification of three new phase II metabolites of a designer drug methylone formed in rats by N-demethylation followed by conjugation with dicarboxylic acids
M. Židková, I. Linhart, M. Balíková, M. Himl, V. Dvořáčková, E. Lhotková, T. Páleníček,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- krysa rodu rattus MeSH
- kyseliny dikarboxylové metabolismus MeSH
- methamfetamin analogy a deriváty farmakokinetika farmakologie MeSH
- metylace MeSH
- nové syntetické drogy farmakokinetika farmakologie MeSH
- potkani Wistar MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
1. Methylone (3,4-methylenedioxy-N-methylcathinone, MDMC), which appeared on the illicit drug market in 2004, is a frequently abused synthetic cathinone derivative. Known metabolic pathways of MDMC include N-demethylation to normethylone (3,4-methylenedioxycathinone, MDC), aliphatic chain hydroxylation and oxidative demethylenation followed by monomethylation and conjugation with glucuronic acid and/or sulphate. 2. Three new phase II metabolites, amidic conjugates of MDC with succinic, glutaric and adipic acid, were identified in the urine of rats dosed subcutaneously with MDMC.HCl (20 mg/kg body weight) by LC-ESI-HRMS using synthetic reference standards to support identification. 3. The main portion of administered MDMC was excreted unchanged. Normethylone, was a major urinary metabolite, of which a minor part was conjugated with dicarboxylic acids. 4. Previously identified ring-opened metabolites 4-hydroxy-3-methoxymethcathinone (4-OH-3-MeO-MC), 3-hydroxy-4-methoxymeth-cathinone (3-OH-4-MeO-MC) and 3,4-dihydroxymethcathinone (3,4-di-OH-MC) mostly in conjugated form with glucuronic and/or sulphuric acids were also detected. 5. Also, ring-opened metabolites derived from MDC, namely, 4-hydroxy-3-methoxycathinone (4-OH-3-MeO-C), 3-hydroxy-4-methoxycathinone (3-OH-4-MeO-C) and 3,4-dihydroxycathinone (3,4-di-OH-C) were identified for the first time in vivo.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18033844
- 003
- CZ-PrNML
- 005
- 20181012111054.0
- 007
- ta
- 008
- 181008s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/00498254.2017.1349964 $2 doi
- 035 __
- $a (PubMed)28665175
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Židková, Monika $u a Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University in Prague , Prague , Czech Republic.
- 245 10
- $a Identification of three new phase II metabolites of a designer drug methylone formed in rats by N-demethylation followed by conjugation with dicarboxylic acids / $c M. Židková, I. Linhart, M. Balíková, M. Himl, V. Dvořáčková, E. Lhotková, T. Páleníček,
- 520 9_
- $a 1. Methylone (3,4-methylenedioxy-N-methylcathinone, MDMC), which appeared on the illicit drug market in 2004, is a frequently abused synthetic cathinone derivative. Known metabolic pathways of MDMC include N-demethylation to normethylone (3,4-methylenedioxycathinone, MDC), aliphatic chain hydroxylation and oxidative demethylenation followed by monomethylation and conjugation with glucuronic acid and/or sulphate. 2. Three new phase II metabolites, amidic conjugates of MDC with succinic, glutaric and adipic acid, were identified in the urine of rats dosed subcutaneously with MDMC.HCl (20 mg/kg body weight) by LC-ESI-HRMS using synthetic reference standards to support identification. 3. The main portion of administered MDMC was excreted unchanged. Normethylone, was a major urinary metabolite, of which a minor part was conjugated with dicarboxylic acids. 4. Previously identified ring-opened metabolites 4-hydroxy-3-methoxymethcathinone (4-OH-3-MeO-MC), 3-hydroxy-4-methoxymeth-cathinone (3-OH-4-MeO-MC) and 3,4-dihydroxymethcathinone (3,4-di-OH-MC) mostly in conjugated form with glucuronic and/or sulphuric acids were also detected. 5. Also, ring-opened metabolites derived from MDC, namely, 4-hydroxy-3-methoxycathinone (4-OH-3-MeO-C), 3-hydroxy-4-methoxycathinone (3-OH-4-MeO-C) and 3,4-dihydroxycathinone (3,4-di-OH-C) were identified for the first time in vivo.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a nové syntetické drogy $x farmakokinetika $x farmakologie $7 D015198
- 650 _2
- $a kyseliny dikarboxylové $x metabolismus $7 D003998
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a methamfetamin $x analogy a deriváty $x farmakokinetika $x farmakologie $7 D008694
- 650 _2
- $a metylace $7 D008745
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a potkani Wistar $7 D017208
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Linhart, Igor $u b Faculty of Chemical Technology , Department of Organic Chemistry, University of Chemistry and Technology , Prague , Czech Republic , and.
- 700 1_
- $a Balíková, Marie $u a Institute of Forensic Medicine and Toxicology, First Faculty of Medicine, Charles University in Prague , Prague , Czech Republic.
- 700 1_
- $a Himl, Michal $u b Faculty of Chemical Technology , Department of Organic Chemistry, University of Chemistry and Technology , Prague , Czech Republic , and.
- 700 1_
- $a Dvořáčková, Veronika $u b Faculty of Chemical Technology , Department of Organic Chemistry, University of Chemistry and Technology , Prague , Czech Republic , and.
- 700 1_
- $a Lhotková, Eva $u c National Institute of Mental Health , Klecany , Czech Republic.
- 700 1_
- $a Páleníček, Tomáš $u c National Institute of Mental Health , Klecany , Czech Republic.
- 773 0_
- $w MED00004746 $t Xenobiotica; the fate of foreign compounds in biological systems $x 1366-5928 $g Roč. 48, č. 6 (2018), s. 618-625
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28665175 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20181008 $b ABA008
- 991 __
- $a 20181012111546 $b ABA008
- 999 __
- $a ok $b bmc $g 1340319 $s 1030838
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 48 $c 6 $d 618-625 $e 20170725 $i 1366-5928 $m Xenobiotica $n Xenobiotica $x MED00004746
- LZP __
- $a Pubmed-20181008